Cadrenal Therapeutics provides Q4 corporate update

Cadrenal Therapeutics provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023. Recent Highlights: Expanded focus for tecarfarin development beyond end-stage kidney disease with atrial fibrillation, to include patients with implanted medical devices such as left ventricular assist devices for heart failure as well as for the treatment of patients with antiphospholipid syndrome who require chronic anticoagulation. These two new potential rare medical conditions increase the total addressable market for tecarfarin in excess of $2Bin the U.S. annually. Engaged The Sage Group to assist the company in exploring strategic partnerships, co-development, and licensing agreements for tecarfarin. Engaged pharmaceutical contract development and manufacturing organizations to supply active pharmaceutical ingredients and clinical trial materials.